Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms... Show more
ICLR moved below its 50-day moving average on October 28, 2025 date and that indicates a change from an upward trend to a downward trend. In of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The 10-day moving average for ICLR crossed bearishly below the 50-day moving average on November 03, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ICLR entered a downward trend on November 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ICLR's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where ICLR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 21, 2025. You may want to consider a long position or call options on ICLR as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ICLR just turned positive on November 21, 2025. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
ICLR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ICLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.345) is normal, around the industry mean (12.405). P/E Ratio (22.152) is within average values for comparable stocks, (134.795). Projected Growth (PEG Ratio) (1.283) is also within normal values, averaging (1.915). ICLR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (1.627) is also within normal values, averaging (9.817).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
a provider of clinical research and development services
Industry MedicalSpecialties
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BJAN | 52.95 | 0.34 | +0.64% |
| Innovator US Equity Buff ETF™ Jan | |||
| MAYP | 30.23 | 0.10 | +0.32% |
| PGIM S&P 500 Buffer 12 ETF - May | |||
| MEAR | 50.40 | 0.03 | +0.06% |
| iShares Short Maturity Muni Bd Act ETF | |||
| INQQ | 15.54 | -0.19 | -1.23% |
| INQQ The India Internet ETF | |||
| MRAL | 6.10 | -0.24 | -3.79% |
| GraniteShares 2x Long MARA Daily ETF | |||
A.I.dvisor indicates that over the last year, ICLR has been closely correlated with TMO. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICLR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To ICLR | 1D Price Change % | ||
|---|---|---|---|---|
| ICLR | 100% | +3.95% | ||
| TMO - ICLR | 67% Closely correlated | +2.57% | ||
| CRL - ICLR | 63% Loosely correlated | +3.43% | ||
| A - ICLR | 62% Loosely correlated | +4.27% | ||
| RGEN - ICLR | 62% Loosely correlated | +5.34% | ||
| DHR - ICLR | 59% Loosely correlated | +2.34% | ||
More | ||||